Evidence map›Paper›PMID 32822602›Full record

ArticleAmerican journal of human genetics2020

De Novo KAT5 Variants Cause a Syndrome with Recognizable Facial Dysmorphisms, Cerebellar Atrophy, Sleep Disturbance, and Epilepsy.

Jonathan Humbert, Smrithi Salian, Periklis Makrythanasis, Gabrielle Lemire, Justine Rousseau, Sophie Ehresmann, Thomas Garcia, Rami Alasiri, Armand Bottani, Sylviane Hanquinet and 8 more

Open access · bronzeAbstract read
In one paragraph

Article in American journal of human genetics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Kat5 cKO mouse replicates biological domain signatures associated with Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. HBO1, a MYSTerious KAT and its links to cancer.Biochimica et biophysica acta. Gene regulatory mechanisms · 2024
    Review
  12. Article
  13. Article
  14. Article
  15. Acetyltransferase in cardiovascular disease and aging.The journal of cardiovascular aging · 2024
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 8 institutions in 4 countries.

Jonathan HumbertSt-Patrick Research Group in Basic Oncology, Laval University Cancer Research Center, Axe Oncologie du Centre de Recherche du Centre Hospitalier Universitaire de Quebec-Université Laval, Quebec City, QC G1R 3S3, Canada.
Smrithi SalianSainte-Justine Hospital Research Center, University of Montreal, Montreal, QC H3T 1C5, Canada.
Periklis MakrythanasisBiomedical Research Foundation of the Academy of Athens, Athens 115 27, Greece; Department of Genetic Medicine and Development, University of Geneva Medical School and Geneva University Hospitals, 1211 Geneva, Switzerland.
Gabrielle LemireSainte-Justine Hospital Research Center, University of Montreal, Montreal, QC H3T 1C5, Canada.
Justine RousseauSainte-Justine Hospital Research Center, University of Montreal, Montreal, QC H3T 1C5, Canada.
Sophie EhresmannSainte-Justine Hospital Research Center, University of Montreal, Montreal, QC H3T 1C5, Canada.
Thomas GarciaSainte-Justine Hospital Research Center, University of Montreal, Montreal, QC H3T 1C5, Canada.
Rami AlasiriRosalind and Morris Goodman Cancer Research Centre, Department of Medicine, McGill University, Montreal, QC H3A 1A3, Canada.
Armand BottaniService of Genetic Medicine, Geneva University Hospitals, 1211 Geneva, Switzerland.
Sylviane HanquinetUnit of Pediatric Radiology, Geneva University Hospitals, 1211 Geneva, Switzerland.
Erin BeaverMercy Kids Genetics, St. Louis, MO 63141, USA.
Jennifer HeeleyMercy Kids Genetics, St. Louis, MO 63141, USA.
Ann C M SmithOffice of the Clinical Director, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20894, USA.
Seth I BergerChildren's National Health System, Washington, DC 20010, USA.
Stylianos E AntonarakisDepartment of Genetic Medicine and Development, University of Geneva Medical School and Geneva University Hospitals, 1211 Geneva, Switzerland.
Xiang-Jiao YangRosalind and Morris Goodman Cancer Research Centre, Department of Medicine, McGill University, Montreal, QC H3A 1A3, Canada.
Jacques CôtéSt-Patrick Research Group in Basic Oncology, Laval University Cancer Research Center, Axe Oncologie du Centre de Recherche du Centre Hospitalier Universitaire de Quebec-Université Laval, Quebec City, QC G1R 3S3, Canada.
Philippe M CampeauSainte-Justine Hospital Research Center, University of Montreal, Montreal, QC H3T 1C5, Canada. Electronic address: p.campeau@umontreal.ca.
Centre Hospitalier Universitaire Sainte-Justine · CACentre hospitalier universitaire de Québec · CAMcGill University Health Centre · CASisters of Mercy Health System · USUniversity Hospital of Geneva · CHUniversity of Geneva · CHChildren's National · USNational Institutes of Health · US

Funding

CIHR FDN-143314
6 · The paper itself

Abstract

KAT5 encodes an essential lysine acetyltransferase, previously called TIP60, which is involved in regulating gene expression, DNA repair, chromatin remodeling, apoptosis, and cell proliferation; but it remains unclear whether variants in this gene cause a genetic disease. Here, we study three individuals with heterozygous de novo missense variants in KAT5 that affect normally invariant residues, with one at the chromodomain (p.Arg53His) and two at or near the acetyl-CoA binding site (p.Cys369Ser and p.Ser413Ala). All three individuals have cerebral malformations, seizures, global developmental delay or intellectual disability, and severe sleep disturbance. Progressive cerebellar atrophy was also noted. Histone acetylation assays with purified variant KAT5 demonstrated that the variants decrease or abolish the ability of the resulting NuA4/TIP60 multi-subunit complexes to acetylate the histone H4 tail in chromatin. Transcriptomic analysis in affected individual fibroblasts showed deregulation of multiple genes that control development. Moreover, there was also upregulated expression of PER1 (a key gene involved in circadian control) in agreement with sleep anomalies in all of the individuals. In conclusion, dominant missense KAT5 variants cause histone acetylation deficiency with transcriptional dysregulation of multiples genes, thereby leading to a neurodevelopmental syndrome with sleep disturbance, cerebellar atrophy, and facial dysmorphisms, and suggesting a recognizable syndrome.

Indexed as

Abnormalities, MultipleAdolescentAdultAtrophyCerebellar DiseasesChild, PreschoolChromatinChromatin Assembly and DisassemblyDNA RepairEpilepsyFemaleHeterozygoteHistonesHumansIntellectual DisabilityLysine Acetyltransferase 5ChromatinHistonesKAT5 protein, humanLysine Acetyltransferase 5brain malformationsepigeneticepilepsyhistonehistone acetyltransferaseintellectual disabilityKAT5sleep disturbanceTIP60

Identifiers

PMID32822602
PMCPMC7477011
OpenAlexW3078866619

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.